The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification.
J. K. Lennerz
No relevant relationships to disclose
E. L. Kwak
Research Funding - Pfizer
M. Michael
No relevant relationships to disclose
S. B. Fox
No relevant relationships to disclose
A. Ackerman
No relevant relationships to disclose
K. Bergethon
No relevant relationships to disclose
G. Y. Lauwers
No relevant relationships to disclose
J. G. Christensen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
K. D. Wilner
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
D. A. Haber
No relevant relationships to disclose
R. Salgia
No relevant relationships to disclose
Y. Bang
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
J. W. Clark
Research Funding - Pfizer
B. J. Solomon
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
A. J. Iafrate
Consultant or Advisory Role - Pfizer